Helium ( DrugBank: Helium )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
228	Bronchiolitis obliterans	1
299	Cystic fibrosis	4
330	Congenital tracheal stenosis	1

228. Bronchiolitis obliterans

---

Clinical trials : 96 /  Drugs : 125 - (DrugBank : 34) / Drug target genes : 33 - Drug target pathways : 155

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02316392 (ClinicalTrials.gov)	December 2014	10/12/2014	Imaging and Understanding BOS in Lung Transplantation	Imaging and Understanding BOS in Lung Transplantation	Bronchiolitis Obliterans Syndrome	Drug: Hyperpolarized Helium-3 MRI	Children's Hospital Medical Center, Cincinnati	NULL	Completed	1 Year	25 Years	All	6	N/A	United States

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02163681 (ClinicalTrials.gov)	January 1, 2011	10/6/2014	MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Children		Healthy;Cystic Fibrosis (CF);Asthma;Bronchopulmonary Dysplasia (BPD)	Drug: Hyperpolarized Helium-3 MRI of the chest	University of Virginia	Xemed LLC	Completed	4 Months	65 Years	All	77	N/A	United States
2	NCT01161537 (ClinicalTrials.gov)	October 2010	9/7/2010	Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation	A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40% Predicted	Cystic Fibrosis	Drug: VX-770;Drug: Placebo	Vertex Pharmaceuticals Incorporated	Cystic Fibrosis Foundation Therapeutics	Completed	12 Years	N/A	All	13	Phase 2	United States
3	NCT00846573 (ClinicalTrials.gov)	November 2008	16/2/2009	Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders	Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders	COPD;Cystic Fibrosis;Asthma;Healthy	Drug: Hyperpolarized Helium-3	University of Massachusetts, Worcester	NULL	Terminated	5 Years	N/A	All	14	N/A	United States
4	EUCTR2017-000672-28-Outside-EU/EEA (EUCTR)		27/03/2017	Study of the Effect of VX-770 on Hyperpolarized Helium-3 MagneticResonance Imaging in Subjects With Cystic Fibrosis and the G551DMutation	A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effectof VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging inSubjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40%Predicted	cystic fibrosis MedDRA version: 19.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Kalydeco Product Name: ivacaftor Product Code: VX-770 INN or Proposed INN: IVACAFTOR	Vertex Pharmaceuticals Incorporated	NULL	NA			Female: yes Male: yes	17	Phase 2	United States

330. Congenital tracheal stenosis

---

Clinical trial : 1 /  Drugs : 3 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JMA-IIA00357	01/07/2018	19/06/2018	Phase II trial of helium / oxygen mixed gas for respiratory failure secondary to airway obstructive lesion in children	Phase II trial of helium / oxygen mixed gas for respiratory failure secondary to airway obstructive lesion in children	Respiratory failure due to airway obstructive lesion such as acute bronchiolitis, congenital tracheal stenosis, bronchial asthma attack	Intervention type:DRUG. Intervention1:Helium / oxygen mixed gas inhalation therapy, Dose form:INSUFFLATION, Route of administration:INHALATIONAL, intended dose regimen:Helium / oxygen mixed gas .	Tokyo Metropolitan Children's Medical Center	National Center for Child Health and Development	Recruiting	No Limit	<20 YEARS	BOTH	15	Phase 2	Japan

Back to top